The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Development Of New Heart Failure Therapeutics By Analysing Signalling In Heart Failure As A Network
Funder
National Health and Medical Research Council
Funding Amount
$314,965.00
Summary
After detailed analysis of cell signalling in diseased heart tissue we will facilitate the discovery of new therapeutic drug targets to stop the progression of heart failure in its early stages. It is hoped that the detailed analysis of heart failure signalling as a network rather than as individual pathways will enable the discovery of drugs which are more successful in stopping the progression of heart failure than the currently available drugs.
Assessing Efficacy Of Polyfunctional Nanoparticles Engineered For The Delivery Of Multiple Therapeutics In Reduction Of Cardiac Ischemia Reperfusion Injury
Funder
National Health and Medical Research Council
Funding Amount
$317,678.00
Summary
A reduction in heart muscle damage after a heart attack is associated with a reduction in heart failure and an increase in life expectancy. However to date many therapeutic agents are not successful at reducing muscle damage because of difficulty in delivering the drugs to the target site. This project will address these delivery issues by making use of multifunctional nanoparticles which will allow for targeted delivery and release of therapeutics directly to damaged tissue following injury.
Type 2 diabetes is the most common endocrine disease in the world and up to 60% of diabetic patients have heart disease. Heart disease is the most expensive heath condition and biggest cause of death in Australia. Diabetic patients often accumulate fat (triglyceride) within their heart cells, leading to diabetic heart disease. The present study sought to determine if diabetic patients with increased fat within their heart cells have more scarring which eventually results heart muscle dysfunction ....Type 2 diabetes is the most common endocrine disease in the world and up to 60% of diabetic patients have heart disease. Heart disease is the most expensive heath condition and biggest cause of death in Australia. Diabetic patients often accumulate fat (triglyceride) within their heart cells, leading to diabetic heart disease. The present study sought to determine if diabetic patients with increased fat within their heart cells have more scarring which eventually results heart muscle dysfunction.Read moreRead less
Early Molecular Causes Of Pathological Cardiac Hypertrophy And Failure
Funder
National Health and Medical Research Council
Funding Amount
$311,860.00
Summary
Pathological increase in heart size is a common condition in Australia. Small regulatory RNAs are now known to have a role in the normal development of the heart. Therefore we want to identify and then test the use of small RNA molecules as prevention and therapy for heart enlargement in an animal model. We will also identify different combinations of changes in the DNA sequence that could be used as markers for the predisposition of increased heart.
Hypertrophic cardiomyopathy (HCM) is the most common genetic heart disease. A new clinical subgroup of HCM patients who are essentially gene carriers, referred to as "Genotype Positive Phenotype Negative" has arisen as a result of genetic testing in at-risk family relatives. Little is known about the natural history and long-term clinical outcomes of this new clinical subgroup. Understanding these factors is vital to the development of management guidelines that will lead to the best possible ou ....Hypertrophic cardiomyopathy (HCM) is the most common genetic heart disease. A new clinical subgroup of HCM patients who are essentially gene carriers, referred to as "Genotype Positive Phenotype Negative" has arisen as a result of genetic testing in at-risk family relatives. Little is known about the natural history and long-term clinical outcomes of this new clinical subgroup. Understanding these factors is vital to the development of management guidelines that will lead to the best possible outcome for these patients.Read moreRead less
Mitochondrial Dysfunction In Cardiac Hypertrophy And Failure
Funder
National Health and Medical Research Council
Funding Amount
$164,821.00
Summary
Heart failure is a disease of wide prevalence in the Western World. In addition to the human toll of heart failure, the economic impact is highly substantial. It remains unclear what causes heart failure, but the effects of calcium and free radicals produced in the mitochondria on muscle function are generally accepted as major contributors. The aim of this project is to understand how calcium and free radicals interact with each other and the mechanisms by which they reduce heart function.